The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A05 | Bile and liver therapy | |
| 3 | A05A | Bile therapy | |
| 4 | A05AX | Other drugs for bile therapy |
| Code | Title | |
|---|---|---|
| A05AX01 | Piprozolin | |
| A05AX02 | Hymecromone | |
| A05AX03 | Cyclobutyrol | |
| A05AX04 | ||
| A05AX05 | ||
| A05AX06 |
| Active Ingredient | Description | |
|---|---|---|
| Maralixibat |
Maralixibat is a minimally absorbed, reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Maralixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. |
|
| Odevixibat |
Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Pharmacodynamic effects odevixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BYLVAY Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LIVMARLI Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC |
